14-1347-82

antibody from Invitrogen Antibodies

Targeting: TNFRSF4 ACT35, CD134, OX40, TXGP1L

Immunohistochemistry (Recommended by provider)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

14-1347-82

Provider

Invitrogen Antibodies

Product name

CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience™

Antibody type

Monoclonal

Antigen

Other

Description

Description: The ACT35 monoclonal antibody reacts with human CD134, also known as OX-40. A member of the TNF receptor superfamily, CD134/OX-40 is a 50 kDa type I membrane glycoprotein expressed by activated T lymphocytes. The interaction of CD134 with OX-40L has been implicated in T cell-dependent humoral response, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool and regulation of tolerance in the CD4^+ T cell compartment. Applications Reported: This ACT35 (ACT-35) antibody has been reported for use in flow cytometric analysis, immunohistology staining of frozen tissue sections, and immunohistology staining of paraffin embedded tissue sections. Applications Tested: The ACT35 (ACT-35) antibody has been tested by flow cytometric analysis of 3-day PHA activated human normal human peripheral blood cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 µm post-manufacturing filtered.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

ACT35 (ACT-35)

Vial size

100 µg

Concentration

0.5 mg/mL

Storage

4° C

References

Submitted references

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.

Autio M, Leivonen SK, Brück O, Mustjoki S, Mészáros Jørgensen J, Karjalainen-Lindsberg ML, Beiske K, Holte H, Pellinen T, Leppä S
Haematologica 2021 Mar 1;106(3):718-729

---

Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients.

Theodoraki MN, Laban S, Jackson EK, Lotfi R, Schuler PJ, Brunner C, Hoffmann TK, Whiteside TL, Hofmann L
British journal of cancer 2021 Dec;125(12):1677-1686

---

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA
NPJ genomic medicine 2017;2

---

ICOS(+) Foxp3(+) TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori.

Nagase H, Takeoka T, Urakawa S, Morimoto-Okazawa A, Kawashima A, Iwahori K, Takiguchi S, Nishikawa H, Sato E, Sakaguchi S, Mori M, Doki Y, Wada H
International journal of cancer 2017 Feb 1;140(3):686-695

---

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA
Oncoimmunology 2016 Mar;5(3):e1136044

---

Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE, Kwak LW, Liu YJ, Neelapu SS
International journal of cancer 2014 Dec 15;135(12):2834-46

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Staining of 2-day PHA-L (Product # 00-4977-93)-stimulated normal human peripheral blood cells with 0.125 µg of Mouse IgG1 kappa Isotype Control (Product # 14-4714-85) (blue histogram) or 0.125 µg of CD134 (OX40) Monoclonal Antibody (purple histogram) followed by IgG Polyclonal Antibody, PE (Product # 12-4010-87). Total viable cells were used for analysis, as determined by 7-AAD (Product # 00-6993-50).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 2 Surface values of immune checkpoints on exosomes isolated from plasma of HNSCC patients. Exosomes from n = 17 HNSCC patients obtained at defined time-points were captured using biotinylated CD63-antibodies and stained with fluorochrome-conjugated antibodies against PD-L1 ( a ), CTLA-4 ( b ), OX40 ( c ) and OX40-L ( d ). Surface values as determined by on-bead flow cytometry are shown as RFI compared to an appropriate isotype control. Results are plotted as box-and-whisker blots representing the median value, the 25th and 75th quartiles and the range. Wilcoxon related samples tests were applied to each compare pre-OP, post-OP, end (C)RT and follow-up. Mann-Whitney test was applied to compare recurrence with follow-up. * or # and ** or ## correspond to p